Client Login

Blog archive for April 2014

All of our blog posts from April 2014

Revised EU Technology Transfer Block Exemption Regulation (TTBER) and Guidelines Adopted

April 2014

The European Commission has adopted new rules for the assessment of technology transfer agreements under EU Competition rules.
Find out more

Updates — In this section

All latest updates

Oxford Bacteriophage Conference 2017
September 2017
HGF Partner Craig Thomson will be Co-presenting "Creating Impact: The challenges and opportunities of commercialisation in the field of bacteriophage research" alongside Professor Martha RJ Clokie.
Read More
IP in Retail Conference 2017
September 2017
IP in Retail 2017 - HGF's fifth annual conference will be held in September in Leeds and London. The conference addresses topical IP issues for retailers.
Read More
CpG Oligonucleotide Therapeutics - A History Lesson for CRISPR?
July 2017
When we look at the emerging and likely future battles being fought to establish dominance in the emerging field of CRISPR technologies, it may be too easy to conclude that one has no frame of reference to help understand what the conclusion will likely be. However, as Harry S Truman said; “There is nothing new in the world except the history you do not know”. There have, of course, been many emerging technologies that have been subject to an IP land-grab. One such instance that we will look at in this article relates to CpG oligonucleotides.
Read More
UPC Agreement Provisional Application Phase and What’s Next
July 2017
The UK has deposited the document required to apply the Protocol to the Agreement on a Unified Patent Court on provisional application (PPA) with the depository for the UPC Agreement.
Read More
UK Patent Equivalents, Exclusions and Estoppel – where are we now?
July 2017
A 5 year battle between Eli Lilly (Lilly) and Actavis centred on Lilly’s patent for the use of pemetrexed disodium for cancer therapy, has culminated in a decision from the UK Supreme Court, allowing Lilly’s appeal and deciding that Actavis' Products directly infringe Eli Lilly's patent in the UK, France, Italy and Spain. The Court also dismissed Actavis' cross-appeal on the basis that if its products did not directly infringe, they would indirectly infringe to the extent held by the Court of Appeal. Full judgment here.
Read More